Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Total Current Liabilities came in at $56.0 million in Q1 2026, up 27.65% year-on-year from $43.9 million in Q1 2025, and up 21.83% quarter-over-quarter from $46.0 million in Q4 2025.
Oculis Holding AG (OCS) Total Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $56.0 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 27.65% year-over-year to $56.0 million in Q1 2026; TTM through Mar 2026 was $56.0 million, a 27.65% increase from a year earlier, with the FY2025 full-year figure at $44.3 million, down 11.85% from the prior year.
- Total Current Liabilities grew to $56.0 million in Q1 2026 per OCS's latest filing, from $46.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $56.0 million in Q1 2026 and bottomed at $12.5 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $32.0 million (2024), against an average of $33.8 million.
- Across the five-year window, Total Current Liabilities surged 183.23% in 2022 and decreased 8.95% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $12.5 million in 2022, then surged by 72.47% to $21.5 million in 2023, then jumped by 134.65% to $50.5 million in 2024, then retreated by 8.95% to $46.0 million in 2025, then climbed by 21.83% to $56.0 million in 2026.
- Per Business Quant, the three latest OCS Total Current Liabilities figures stand at $56.0 million (Q1 2026), $46.0 million (Q4 2025), and $42.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.01 Mn |
| Dec 31, 2025 | 45.98 Mn |
| Sep 30, 2025 | 42.16 Mn |
| Jun 30, 2025 | 44.14 Mn |
| Mar 31, 2025 | 43.88 Mn |
| Dec 31, 2024 | 50.50 Mn |
| Sep 30, 2024 | 31.99 Mn |
| Jun 30, 2024 | 26.13 Mn |
| Mar 31, 2024 | 20.80 Mn |
| Dec 31, 2023 | 21.52 Mn |
| Sep 30, 2023 | 25.08 Mn |
| Jun 30, 2023 | 18.69 Mn |
| Dec 31, 2022 | 12.48 Mn |
| Dec 31, 2021 | 4.41 Mn |